Near point-of-care nucleic acid amplification tests (NPOC-NAATs) using respiratory specimens for detection of pulmonary tuberculosis.
David J Horne, Jerry S Zifodya, Ermias Diro Ejara et al.
✦ AI-curated · Sources linked
In 30 seconds
This Cochrane systematic review and meta-analysis assessed near point-of-care nucleic acid amplification testing for pulmonary tuberculosis in adults, adolescents, and children with presumptive disease. Five studies from nine moderate- to high-burden countries included 3291 participants; all evaluated the MTB NAT Card on Pluslife Thermolyse and MiniDock devices, using sputum. Against culture, MiniDock had a summary sensitivity of 85.4% (95% CI 82.2 to 88.1) and specificity of 97.6% (95% CI 96.9 to 98.1), with moderate-certainty evidence. The review noted that most testing took place in laboratories rather than peripheral healthcare settings.
Key findings
- Across five studies and 3291 participants, MiniDock sensitivity against culture was 85.4% (95% CI 82.2 to 88.1).
- Summary specificity against culture was 97.6% (95% CI 96.9 to 98.1), based on moderate-certainty evidence.
- All included studies assessed the MTB NAT Card with Pluslife devices, and sputum was the only specimen type with available data.
Why it matters
A battery-operated molecular test with high summary specificity and useful sensitivity could support pulmonary tuberculosis diagnosis where laboratory infrastructure is limited. However, the evidence chiefly establishes accuracy under study conditions, not performance in routine peripheral care. The distinction matters when interpreting whether these results can translate to settings where the tests are intended to be used.
What to keep in mind
Evidence covered one marketed test and sputum only. Most studies performed testing in laboratories rather than peripheral settings, raising applicability concerns.